Clinical and transplant characteristics of HSCT recipients
| ID . | Recipient age (y)/sex . | Diagnosis . | Donor age (y)/sex . | Conditioning regimen . | Cell dose × 108/kg* . | ANC/platelet† recovery (d) . | Acute/chronic GVHD . | Outcome‡ . |
|---|---|---|---|---|---|---|---|---|
| 1 | 51/F | AML | 29/F | BU/CY | 4.0 | 15/22 | I/0 | Died |
| 2 | 45/F | NHL | 50/F | BU/CY | 6.8 | 19/36 | III/E | EFS |
| 3 | 53/M | AML | 56/F | CY/TBI | 2.5 | 21/33 | I/E | EFS |
| 4 | 43/M | CLL | 55/F | BU/CY | 2.6 | 19/24 | II/0 | EFS |
| 5 | 58/M | CML | 62/F | CY/TBI/AraC | 1.7 | 23/18 | II/0 | EFS |
| 6 | 56/F | NHL | 61/F | BU/CY | 3.0 | 27/25 | 0/0 | EFS |
| 7 | 42/M | CML | 36/F | BU/CY | 3.0 | 26/22 | I/E | EFS |
| 8 | 55/F | NHL | 43/F | BU/CY | 2.6 | 22/37 | II/0 | EFS |
| 9 | 23/M | NHL | 30/F | CY/TBI | 2.5 | 34/23 | II/0 | EFS |
| 10 | 12/M | AML | 10/F | CY/TBI | 2.5 | 14/13 | 0/E | EFS |
| 11 | 52/F | CML | 46/F | BU/CY | 3.2 | 28/22 | II/E | EFS |
| 12 | 11/M | ALL | 13/M | CY/TBI | 2.7 | 14/24 | 0/0 | EFS |
| 13 | 18/M | AML | 45/M | BU/CY | 2.8 | 16/63 | III/E | EFS |
| 14 | 40/M | ALL | 56/F | CY/TBI | 2.8 | 17/17 | II/E | EFS |
| 15 | 38/M | MF | 37/F | CY/TBI | 3.4 | 19/23 | II/E | EFS |
| 16 | 55/F | CML | 52/M | CY/TBI/AraC | 1.0 | 21/19 | III/E | Died |
| 17 | 50/M | NHL | 42/M | BU/CY | 3.8 | 15/20 | II/E | EFS |
| 18 | 55/M | CML | 45/M | BU/CY | 2.9 | 25/20 | I/L | EFS |
| 19 | 49/M | CML | 46/F | BU/CY | 2.6 | 19/15 | I/L | EFS |
| 20 | 54/M | AML | 49/M | BU/CY | 2.2 | 21/23 | I/0 | EFS |
| 21 | 36/M | MDS | 30/M | CY/TBI | 3.5 | 24/— | 0/— | Died |
| 22 | 42/F | MDS | 40/M | BU/CY | 2.8 | 24/— | II/E | Died |
| 23 | 52/M | PLL | 65/M | BU/CY | 2.0 | 27/24 | 0/— | EFS |
| 24 | 52/F | AML | 50/M | VP-16/TBI | 3.8 | 19/28 | II/— | EFS |
| 25 | 46/M | CML | 49/M | CY/TBI | 2.9 | 18/19 | II/— | EFS |
| ID . | Recipient age (y)/sex . | Diagnosis . | Donor age (y)/sex . | Conditioning regimen . | Cell dose × 108/kg* . | ANC/platelet† recovery (d) . | Acute/chronic GVHD . | Outcome‡ . |
|---|---|---|---|---|---|---|---|---|
| 1 | 51/F | AML | 29/F | BU/CY | 4.0 | 15/22 | I/0 | Died |
| 2 | 45/F | NHL | 50/F | BU/CY | 6.8 | 19/36 | III/E | EFS |
| 3 | 53/M | AML | 56/F | CY/TBI | 2.5 | 21/33 | I/E | EFS |
| 4 | 43/M | CLL | 55/F | BU/CY | 2.6 | 19/24 | II/0 | EFS |
| 5 | 58/M | CML | 62/F | CY/TBI/AraC | 1.7 | 23/18 | II/0 | EFS |
| 6 | 56/F | NHL | 61/F | BU/CY | 3.0 | 27/25 | 0/0 | EFS |
| 7 | 42/M | CML | 36/F | BU/CY | 3.0 | 26/22 | I/E | EFS |
| 8 | 55/F | NHL | 43/F | BU/CY | 2.6 | 22/37 | II/0 | EFS |
| 9 | 23/M | NHL | 30/F | CY/TBI | 2.5 | 34/23 | II/0 | EFS |
| 10 | 12/M | AML | 10/F | CY/TBI | 2.5 | 14/13 | 0/E | EFS |
| 11 | 52/F | CML | 46/F | BU/CY | 3.2 | 28/22 | II/E | EFS |
| 12 | 11/M | ALL | 13/M | CY/TBI | 2.7 | 14/24 | 0/0 | EFS |
| 13 | 18/M | AML | 45/M | BU/CY | 2.8 | 16/63 | III/E | EFS |
| 14 | 40/M | ALL | 56/F | CY/TBI | 2.8 | 17/17 | II/E | EFS |
| 15 | 38/M | MF | 37/F | CY/TBI | 3.4 | 19/23 | II/E | EFS |
| 16 | 55/F | CML | 52/M | CY/TBI/AraC | 1.0 | 21/19 | III/E | Died |
| 17 | 50/M | NHL | 42/M | BU/CY | 3.8 | 15/20 | II/E | EFS |
| 18 | 55/M | CML | 45/M | BU/CY | 2.9 | 25/20 | I/L | EFS |
| 19 | 49/M | CML | 46/F | BU/CY | 2.6 | 19/15 | I/L | EFS |
| 20 | 54/M | AML | 49/M | BU/CY | 2.2 | 21/23 | I/0 | EFS |
| 21 | 36/M | MDS | 30/M | CY/TBI | 3.5 | 24/— | 0/— | Died |
| 22 | 42/F | MDS | 40/M | BU/CY | 2.8 | 24/— | II/E | Died |
| 23 | 52/M | PLL | 65/M | BU/CY | 2.0 | 27/24 | 0/— | EFS |
| 24 | 52/F | AML | 50/M | VP-16/TBI | 3.8 | 19/28 | II/— | EFS |
| 25 | 46/M | CML | 49/M | CY/TBI | 2.9 | 18/19 | II/— | EFS |
ANC, absolute neutrophil count; GVHD, graft-versus-host disease; acute GVHD graded I-IV39; chronic GVHD classified L (limited) or E (extensive)40; AML, acute myeloid leukemia; BU, busulphan; CY, cyclophosphamide; NHL, non-Hodgkin lymphoma; EFS, event-free survival; TBI, total body irradiation (fractionated when combined with CY or VP-16 alone, otherwise single dose); CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; AraC, cytarabine; ALL, acute lymphoblastic leukemia; MF, myelofibrosis; MDS, myelodysplasia; PLL, prolymphocytic leukemia; —, not performed; VP-16, etoposide.
Nucleated cell dose (all bone marrow grafts, except mobilized peripheral blood for R19).
Recovery of ANC to > 0.5 × 109/L and unsupported platelets of > 20 × 109/L.
Patients followed until death or for 1 year, except R23-R25 followed for 60 days; deaths were transplantation related in R16 and R21, and because of relapse in R1 and R22.